Petros Pharmaceuticals, Inc.
Petros Pharmaceuticals, Inc. (PTPI): 1 pipeline candidate · ~17 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
16.7 months
D/E 1.48 · 9% dilution
Lead: Approved
1 candidate
N/A
N/A
A transparent, data-derived signal for Petros Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$254K
Cash
$4.4M
Quarterly Burn
$784K
Runway
16.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| stendra | Approved |
Frequently asked questions
How many drug candidates are in Petros Pharmaceuticals, Inc.'s pipeline?
Petros Pharmaceuticals, Inc. (PTPI) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Petros Pharmaceuticals, Inc.'s lead drug candidate?
Petros Pharmaceuticals, Inc.'s most advanced tracked candidate is stendra (Approved) for Erectile dysfunction (ED).
What is Petros Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Petros Pharmaceuticals, Inc. has approximately 16.7 months of cash runway.
What is Petros Pharmaceuticals, Inc.'s market capitalization?
Petros Pharmaceuticals, Inc.'s market capitalization is approximately $254K.
Who is the CEO of Petros Pharmaceuticals, Inc.?
Exchange Act is the chief executive officer of Petros Pharmaceuticals, Inc. (PTPI).
Get the full picture on Petros Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.